In HFD–fed mice, systemic administration of SHLP2 via intraperitoneal (IP) injection improved glucose tolerance and insulin signaling, reduced hepatic lipogenic gene expression and steatosis, increased energy expenditure, and suppressed food intake.65 The gene discussed is INS; the disease is steatosis.